Future treatment options for atopic dermatitis - Small molecules and beyond

Journal of Dermatological Science

Volumn 73, Issue 2, 2014, Pages 91-100

  Schäkel, Knut ^a   Döbel, Thomas ^a   Bosselmann, Ina ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Atopic dermatitis; IgE; Pruritus; Review; Th2; Therapy

Indexed keywords

ALEFACEPT; AMG 157; AN 2728; AN 2898; ANTIHISTAMINIC AGENT; APREMILAST; BAY 169996; CD2 ANTIGEN; CHYMASE; CYCLIC AMP; DUPILUMAB; ENZYME INHIBITOR; IMMUNOGLOBULIN E; INTERLEUKIN 1BETA; INTERLEUKIN 4 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAPRACORAT; MONOCLONAL ANTIBODY; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PHOSPHODIESTERASE IV INHIBITOR; PITRAKINRA; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SUN 13350; SUN 13834; SUN C8257; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROCANIC ACID; WBI 1001;

ABSENCE OF SIDE EFFECTS; ATOPIC DERMATITIS; DEGRADATION KINETICS; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HEADACHE; HUMAN; LOOSE FECES; NAUSEA; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; REVIEW;

ATOPIC DERMATITIS; IGE; PRURITUS; REVIEW; TH2; THERAPY;

ADMINISTRATION, TOPICAL; ADULT; ALLERGENS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CLINICAL TRIALS AS TOPIC; CYTOKINES; DERMATITIS, ATOPIC; DERMATOLOGY; DRUG DESIGN; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION; PRURITUS; SKIN DISEASES; TH2 CELLS; TREATMENT OUTCOME;

EID: 84891663624     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.11.009     Document Type: Review

References (88)

1. Denby K.S., Beck L.A. Update on systemic therapies for atopic dermatitis. Curr Opin Allergy Clin Immunol 2012, 12:421-426.
2. Bieber T. Atopic dermatitis. N Engl J Med 2008, 358:1483-1494.
3. Mihara K., Kuratani K., Matsui T., Nakamura M., Yokota K. Vital role of the itch-scratch response in development of spontaneous dermatitis in NC/Nga mice. Br J Dermatol 2004, 151:335-345.
4. Ong PY. Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs 2009.
5. Darsow U., Wollenberg A., Simon D., Taieb A., Werfel T., Oranje A., et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010, 24:317-328.
6. Leung D.Y.M., Boguniewicz M., Howell M.D., Nomura I., Hamid Q.A. New insights into atopic dermatitis. J Clin Invest 2004, 113:651-657.
7. Gittler J.K., Shemer A., Suarez-Farinas M., Fuentes-Duculan J., Gulewicz K.J., Wang C.Q., et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012, 130:1344-1354.
8. Bowcock A.M., Cookson W.O.C.M. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004, 13:R43-R55.
9. Palmer C.N.A., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38:441-446.
10. Ikoma A., Steinhoff M., Ständer S., Yosipovitch G., Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006, 7:535-547.
11. Conti M., Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007, 76:481-511.
12. Schett G., Sloan V.S., Stevens R.M., Schafer P. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis 2010, 2:271.
13. Eigler A., Siegmund B., Emmerich U., Baumann K.H., Hartmann G., Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 1998, 63:101-107.
14. Essayan D.M., Huang S.K., Kagey-Sobotka A., Lichtenstein L.M. Differential efficacy of lymphocyte-and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J Allergy Clin Immunol 1997, 99:28-37.
15. Essayan D.M., Huang S.K., Undem B.J., Kagey-Sobotka A., Lichtenstein L.M. Modulation of antigen-and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994, 153:3408.
16. Schafer P., Parton A., Gandhi A., Capone L., Adams M., Wu L., et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010, 159:842-855.
17. Gottlieb A., Strober B., Krueger J., Rohane P., Zeldis J., Hu C., et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008, 24:1529-1538.
18. Samrao A., Berry T.M., Goreshi R., Simpson E.L. A pilot study of an oral phosphodiesterase inhibitor (Apremilast) for atopic dermatitis in adults. Arch Dermatol 2012, 148:890-897.
19. Volf E., Au S., Dumont N., Scheinman P., Gottlieb A. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol 2012, 11:341.
20. Nazarian R., Weinberg J.M. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009, 10:1236.
21. Nakamura H., Aoki M., Tamai K., Oishi M., Ogihara T., Kaneda Y., et al. Prevention and regression of atopic dermatitis by ointment containing NF-κB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Therapy 2002, 9:1221.
22. Dajee M., Muchamuel T., Schryver B., Oo A., Alleman-Sposeto J., De Vry C.G., et al. Blockade of experimental atopic dermatitis via topical NF-κB decoy oligonucleotide. J Invest Dermatol 2006, 126:1792-1803.
23. Schäcke H., Zollner T., Döcke W., Rehwinkel H., Jaroch S., Skuballa W., et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Brit J Pharmacol 2009, 158:1088-1103.
24. Cavet M.E., Harrington K.L., Ward K.W., Zhang J.Z. Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells. Mol Vis 2010, 16:1791-1800.
25. Gibbs N.K., Tye J., Norval M. Recent advances in urocanic acid photochemistry, photobiology and photoimmunology. Photochem Photobiol Sci 2008, 7:655-667.
26. Norval M., Simpson T., Bardshiri E., Crosby J. Quantification of uranic acid isomers in human stratum corneum. Photodermatology 1989, 6:142-145.
27. Prater M., Blaylock B., Holladay S. Molecular mechanisms of cis-urocanic acid and permethrin-induced alterations in cutaneous immunity. Photodermatol Photoimmunol Photomed 2003, 19:287-294.
28. Lauerma A., Aioi A., Maibach H. Topical cis-urocanic acid suppresses both induction and elicitation of contact hypersensitivity in BALB/C mice. Acta Derm Venereol 1995, 75:272.
29. Kaneko K., Smetana-Just U., Matsui M., Young A.R., John S., Norval M., et al. cis-Urocanic acid initiates gene transcription in primary human keratinocytes. J Immunol 2008, 181:217.
30. Kaneko K., Walker S.L., Lai-Cheong J., Matsui M.S., Norval M., Young A.R. cis-Urocanic acid enhances prostaglandin E2 release and apoptotic cell death via reactive oxygen species in human keratinocytes. J Investig Dermatol 2011, 131:1262-1271.
31. Shreedhar V., Giese T., Sung V.W., Ullrich S.E. A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppression. J Immunol 1998, 160:3783.
32. Harriott-Smith T.G., Halliday W. Suppression of contact hypersensitivity by short-term ultraviolet irradiation: II. The role of urocanic acid. Clin Exp Immunol 1988, 72:174.
33. Hart P.H., Grimbaldeston M.A., Finlay-Jones J.J. Mast cells in UV-B-induced immunosuppression. J Photochem Photobiol B: Biol 2000, 55:81-87.
34. Kivistö K., Punnonen K., Toppari J., Leino L. Urocanic acid suppresses the activation of human neutrophils in vitro. Inflammation 1996, 20:451-459.
35. Rinaldi M., Moroni P., Leino L., Laihia J., Paape M., Bannerman D.D. Effect of cis-urocanic acid on bovine neutrophil generation of reactive oxygen species. J Dairy Sci 2006, 89:4188-4201.
36. Filipec M., Letko E., Hašková Z., Jeníčková D., Holler P., Jančárek A., et al. The effect of urocanic acid on graft rejection in an experimental model of orthotopic corneal transplantation in rabbits. Graefes Arch Clin Exp Ophthalmol 1998, 236:65-68.
37. Dahl M.V., McEwen G.N., Katz H.I. Urocanic acid suppresses induction of immunity in human skin. Photodermatol Photoimmunol Photomed 2010, 26:303-310.
38. Bissonnette R., Chen G., Bolduc C., Maari C., Lyle M., Tang L., et al. Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. Arch Dermatol 2010, 146:446.
39. Bissonnette R., Poulin Y., Zhou Y., Tan J., Hong H., Webster J., et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicenter, randomized, placebo-controlled double-blind trial. Brit J Dermatol 2011.
40. Miller G.T., Hochman P.S., Meier W., Tizard R., Bixler S.A., Rosa M.D., et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993, 178:211-222.
41. Bierer't B.E., Burakoff S.J. T cell receptors: adhesion and signaling. Adv Cancer Res 1991, 56:49.
42. Dustin M.L., Springer T.A. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Ann Rev Immunol 1991, 9:27-66.
43. Jenkins M.K., Taylor P.S., Norton S.D., Urdahl K.B. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991, 147:2461.
44. Cooper J.C., Morgan G., Harding S., Subramanyam M., Majeau G.R., Moulder K., et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 2003, 33:666-675.
45. Moul D.K., Routhouska S.B., Robinson M.R., Korman N.J. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008, 58:984-989.
46. Simon D., Wittwer J., Kostylina G., Buettiker U., Simon H.-U., Yawalkar N. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008, 122:423-424.
47. Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013.
48. Radin A., Ren H., Papino-Wood P., Chaudhry U., Hamilton J.D. First-in-human study of REGN668/SAR231893 (IL-4Rα mAb): safety, tolerability and biomarker results of a randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. J Allergy Clin Immunol 2013, 131:AB158.
49. Wenzel S., Wilbraham D., Fuller R., Getz E.B., Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370:1422-1431.
50. Groves R., Wilbraham D., Fuller R., Longphre M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema [abstract# 320]. J Invest Dermatol 2007, 127:S54.
51. Vigo P.G., Girgis K.R., Pfuetze B.L., Critchlow M.E., Fisher J., Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006, 55:168.
52. Belloni B., Ziai M., Lim A., Lemercier B., Sbornik M., Weidinger S., et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007, 120:1223-1225.
53. Heil P.M., Maurer D., Klein B., Hultsch T., Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010, 8:990-998.
54. Welle M. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol 1997, 61:233-245.
55. Tomimori Y., Muto T., Fukami H., Saito K., Horikawa C., Tsuruoka N., et al. Chymase participates in chronic dermatitis by inducing eosinophil infiltration. Lab Invest 2002, 82:789-794.
56. Tomimori Y., Muto T., Fukami H., Saito K., Horikawa C., Tsuruoka N., et al. Mast cell chymase regulates dermal mast cell number in mice. Biochem Biophys Res Commun 2002, 290:1478-1482.
57. Mao X.Q., Shirakawa T., Yoshikawa T., Yoshikawa K., Kawai M., Sasaki S., et al. Association between genetic variants of mast-cell chymase and eczema. Lancet 1996, 348:581-583.
58. Tanaka K., Sugiura H., Uehara M., Sato H., Hashimoto-Tamaoki T., Furuyama J. Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease. Clin Exp Allergy 1999, 29:800-803.
59. Weidinger S., Rummler L., Klopp N., Wagenpfeil S., Baurecht H.J., Fischer G., et al. Association study of mast cell chymase polymorphisms with atopy. Allergy 2005, 60:1256-1261.
60. Tomimori Y., Tsuruoka N., Fukami H., Saito K., Horikawa C., Saito M., et al. Role of mast cell chymase in allergen-induced biphasic skin reaction. Biochem Pharmacol 2002, 64:1187.
61. Watanabe N., Tomimori Y., Saito K., Miura K., Wada A., Tsudzuki M., et al. Chymase inhibitor improves dermatitis in NC/Nga mice. Int Arch Allergy Immunol 2002, 128:229-234.
62. Watanabe N., Tomimori Y., Terakawa M., Ishiwata K., Wada A., Muto T., et al. Oral administration of chymase inhibitor improves dermatitis in NC/Nga mice. J Invest Dermatol 2007, 127:971-973.
63. Terakawa M., Fujieda Y., Tomimori Y., Muto T., Tanaka T., Maruoka H., et al. Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis. Eur J Pharmacol 2008, 601:186-191.
64. Tani K., Ogushi F., Kido H., Kawano T., Kunori Y., Kamimura T., et al. Chymase is a potent chemoattractant for human monocytes and neutrophils. J Leukoc Biol 2000, 67:585-589.
65. Longley B.J., Tyrrell L., Ma Y., Williams D.A., Halaban R., Langley K., et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci U S A 1997, 94:9017.
66. Bergasa N.V., Alling D.W., Talbot T.L., Swain M.G., Yurdaydin C., Turner M.L., et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind, randomized, controlled trial. Ann Intern Med 1995, 123:161-167.
67. Metze D., Reimann S., Beissert S., Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999, 41:533-539.
68. Terg R., Coronel E., Sordá J., Muñoz A.E., Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002, 37:717-722.
69. Pauli-Magnus C., Mikus G., Alscher D.M., Kirschner T., Nagel W., Gugeler N., et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000, 11:514-519.
70. Peer G., Kivity S., Agami O., Fireman E., Silverberg D., Blum M., et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996, 348:1552-1554.
71. Kjellberg F., Tramer M. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001, 18:346-357.
72. Monroe E.W. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 1989, 21:135.
73. Bergasa N.V., Schmitt J.M., Talbot T.L., Alling D.W., Swain M.G., Turner M.L., et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998, 27:679-684.
74. Herzog J.L., Solomon J.A., Draelos Z., Fleischer A., Stough D., Wolf D.I., et al. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (SRD174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis. J Drugs Dermatol 2011, 10:853.
75. Arai I., Takano N., Hashimoto Y., Futaki N., Sugimoto M., Takahashi N., et al. Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2004, 505:229-235.
76. Honma Y., Arai I., Hashimoto Y., Futaki N., Sugimoto M., Tanaka M., et al. Prostaglandin D2 and prostaglandin E2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice. Eur J Pharmacol 2005, 518:56-62.
77. Arai I., Takaoka A., Hashimoto Y., Honma Y., Koizumi C., Futaki N., et al. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice. Eur J Pharmacol 2007, 556:207-214.
78. Sugimoto M., Arai I., Futaki N., Hashimoto Y., Sakurai T., Honma Y., et al. The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice. Eur J Pharmacol 2007, 564:196-203.
79. Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.
80. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995, 92:3376.
81. Johanek L.M., Simone D.A. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain 2004, 109:432-442.
82. Diaz-Laviada I., Ruiz-Llorente L. Signal transduction activated by cannabinoid receptors. Mini Rev Med Chem 2005, 5:619-630.
83. Dvorak M., Watkinson A., McGlone F., Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003, 52:238-245.
84. Rukwied R., Watkinson A., McGlone F., Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003, 102:283-288.
85. Gerspacher M., La Vecchia L., Mah R., von Sprecher A., Anderson G.P., Subramanian N., et al. Dual neurokinin NK1/NK2 antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl) carbamoyl] allyl-N-methyl-3,5-bis (trifluoromethyl) benzamides and 3-[N'-3,5-bis (trifluoromethyl) benzoyl-N-arylmethyl-N'-methylhydrazino]-N-[(R)-2-oxo-azepan-3-yl] propionamides. Bioorg Med Chem Lett 2001, 11:3081-3084.
86. Joos G., Vincken W., Louis R., Schelfhout V., Wang J., Shaw M., et al. Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Res J 2004, 23:76-81.
87. Schmitt J., Meurer M., Schwanebeck U., Grählert X., Schäkel K. Treatment following an evidence-based algorithm versus individualised symptom-oriented treatment for atopic eczema. Dermatology 2008, 217:299-308.
88. Jariwala S., Abrams E., Benson A., Fodeman J., Zheng T. The role of thymic stromal lymphopoietin in the immunopathogenesis of atopic dermatitis. Clin Exp Allergy 2011.